The Ins and Outs of Endocytosis inhibition: Providing diverse opportunities for treatment of incurable cancers
The Ins and Outs of Endocytosis inhibition: Providing diverse opportunities for treatment of incurable cancers
批准号:
nhmrc : 2001396
负责人:
金额:
$91.24万
依托单位国家:
澳大利亚
项目类别:
Ideas Grants
财政年份:
2021
资助国家:
澳大利亚
项目状态:
已结题
起止时间:
2021-01-01 至 2024-12-31
中文摘要
最好的新型免疫系统抗癌药物仅对约30%的患者有效。我们找到了一种方法,可以暂时在人们的肿瘤中移动药物靶点,以逆转耐药性,并在临床试验中进行了测试。在这里,我们建议使用免疫学和世界前沿的电子显微镜技术来精确地计算出肿瘤、免疫细胞和抗癌药物在真实的临床情况下相互作用时会发生什么。目标是达到至少60%的患者应答率。
英文摘要
The best new immune system anti-cancer drugs only work in ~30% of patients. We found a way to move the drug targets around in people's tumours temporarily to reverse resistance and have tested this in clinical trials. Here we propose to use immunology and the world's frontier electron microscope techniques to work out exactly what is happens to the tumours, immune cells and anti-cancer drugs when they interact in real clinical situations. The aim is to reach at least 60% patient response rate.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金